| Zhang, Xiaoshi |
NCT05690035: Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer |
|
|
| Withdrawn | 2 | 12 | RoW | Tislelizumab & Fruquintinib | Sun Yat-sen University, Hutchmed, BeiGene | Metastatic Colorectal Cancer, mCRC | 07/25 | 07/25 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/25 | 09/25 | | |
TAL-T, NCT06302062: Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors |
|
|
| Recruiting | 1 | 23 | RoW | Tumor Associated Lymph node T cell, TAL-T cells, TAL-T, cyclophosphamide, IL-2, Cellular interleukin 2, interleukin-2, Serplulimab Injection, PD1 monoclonal antibody, PD1 | Guangzhou FineImmune Biotechnology Co., LTD. | Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy | 12/25 | 06/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT03891706: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | tumor-specific TCR-T cells, TCR-T cells, FIT-001, Interleukin-2, IL-2 | Guangzhou FineImmune Biotechnology Co., LTD., Sun Yat-sen University | Solid Tumor | 10/25 | 12/25 | | |
NCT06716619: A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | 1 | 32 | RoW | Tumor Associated Lymph node T cell, TAL-T, TAL-T cells, Serplulimab Injection | Guangzhou FineImmune Biotechnology Co., LTD., Sun Yat-sen University | Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection | 12/26 | 12/27 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
